Genitourinary Syndrome of Menopause (GSM) Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 1.60 Bn

Forecast Year, 2035

USD 3.21 Bn

CAGR, 2026 - 2035

7.20%

Report Coverage

Global

What is the Genitourinary Syndrome of Menopause (GSM) Market Size in 2026?

The global genitourinary syndrome of menopause (GSM) market size was calculated at USD 1.60 billion in 2025 and is predicted to increase from USD 1.72 billion in 2026 to approximately USD 3.21 billion by 2035, expanding at a CAGR of 7.20% from 2026 to 2035. The genitourinary syndrome of menopause (GSM) market is growing due to rising awareness of menopausal health and wider availability of therapies.

Key Takeaways

• North America dominated the genitourinary syndrome of menopause (GSM) market in 2025, with 36.70% share.
• Asia-Pacific is expected to be the fastest-growing region between 2026 and 2035.
• By treatment type, vaginal estrogen therapies segment registered its dominance over the global market with a share of 38.60% in 2025.
• By treatment type, the energy-based devices and procedures segment is expected to witness the fastest growth in the market over
• the forecast period.
• By delivery modality, the prescription therapies segment held a dominant position in the market with a share of 56.70% in 2025.
• By delivery modality, the device-based procedures segment is expected to grow at the fastest CAGR during the forecast period.
• By indication, the vaginal dryness and irritation segment dominated the market with a share of 34.60% in 2025.
• By indication, the urinary symptoms segment is expected to show the fastest growth over the forecast period.
• By distribution channel, the retail pharmacy segment led the global market with a share of 44.60% in 2025.
• By distribution channel, the online pharmacy and e-commerce segment is expected to witness the fastest growth in the market over the forecast period.
• By end user, the hospitals segment registered its dominance over the global genitourinary syndrome of menopause (GSM) market with a share of 46.80% in 2025.
• By end user, the home care and self-care segment is expected to expand rapidly in the market in the coming years.

Market Overview

The genitourinary syndrome of menopause (GSM) market covers products and procedures used to manage chronic vulvovaginal and lower urinary tract symptoms associated with estrogen decline after menopause. It includes prescription therapies such as local vaginal estrogens, oral SERMs, and vaginal DHEA, along with OTC moisturisers and lubricants, plus energy-based device procedures offered in women's health clinics. Market revenues span product sales, dispensing channels, and procedural service delivery across hospitals, clinics, and self-care settings.

What is the Role of AI in the Market?

Artificial intelligence is changing the genitourinary syndrome of menopause (GSM) market. AI helps to analyze large amounts of data to predict personalized treatment. Machine learning models, such as telehealth tools and tracking apps, identify abnormal signs, which facilitate early detection and treatment. In pharmaceutical research, AI-powered tools can help scientists to review clinical results more efficiently

What are the Market Trends?

• The genitourinary syndrome of menopause (GSM) market is influenced by rising research and drug development by pharmaceutical companies to develop innovative therapies for GSM and related menopausal conditions.
• Rising awareness of menopause-related health issues by healthcare campaigns, educational programs, and digital health platform are gaining attention to genitourinary syndrome of menopause.
• Patients and healthcare professionals prefer non-hormonal therapies like selective local vaginal estrogens, oral SERMs, and vaginal DHEA, along with OTC moisturisers that relieve symptoms without systemic hormonal exposure.
• The growing population of postmenopausal women is influencing the market.

Market Scope

Segmental Insights

Treatment Insights

What made the Vaginal Estrogen Therapies Segment Lead the Market?

The vaginal estrogen therapies segment registered its dominance over the global genitourinary syndrome of menopause (GSM) market with a share of 38.60% in 2025. Doctors often recommend vaginal estrogen therapies as they directly address the hormonal changes responsible for vaginal dryness, irritation, and thinning of the vaginal lining. The treatment is available as creams, tablets, and vaginal rings that release a small dose of estrogen. Because of its effectiveness, vaginal estrogen therapies are preferred by doctors for long-term treatment.

Genitourinary Syndrome of Menopause Market Share, By Treatment Type, 2025 (%)

The energy-based devices and procedures segment is expected to gain the highest CAGR in the market between 2026 and 2035. The energy-based devices and procedures are the alternative treatment options for women seeking non-hormonal therapy. These procedures use technology such as laser or radiofrequency devices to deliver controlled heat to vaginal tissue. The thermal energy stimulates collagen production and improves blood flow.

Delivery Modality Insights

How the Prescription Therapies Segment Dominated the Market?

The prescription therapies segment led the global genitourinary syndrome of menopause (GSM) market with a share of 56.70% in 2025. Doctors commonly prescribe medications that directly address the hormonal and tissue changes linked with menopause. These include vaginal estrogen products, tablets, and prescription-based drugs to improve vaginal lubrication, reduce irritation, and restore tissue strength. Prescription therapy remains the preferred choice for managing genitourinary syndrome of menopause.

Genitourinary Syndrome of Menopause Market Share, By Delivery Modality, 2025 (%)

The device-based procedures segment is expected to witness the fastest growth in the market with a CAGR over the forecast period. This treatment involves the use of medical devices that deliver controlled energy to the vaginal tissue. The laser therapy improves vascularization of the vaginal mucosa and stimulates the synthesis of new collagen. This is an alternative for women who avoid hormonal interventions in GSM treatment.

Indication Focus Insights

Why Did the Vaginal Dryness and Irritation Segment Hold the Largest Share of the Market?

The vaginal dryness and irritation segment accounted for a considerable revenue share of 34.60% in the genitourinary syndrome of menopause (GSM) market in 2025. It is one of the most common symptoms linked with genitourinary syndrome of menopause. As estrogen levels fall after menopause, the vaginal lining becomes thin and loses its natural moisture. This leads to persistent drying, irritation, burning, and discomfort, especially during intimacy. Due to discomfort, women seek treatment such as lubricants and moisturisers that restore moisture and improve tissue health.

Genitourinary Syndrome of Menopause Market Share, By Indication Focus, 2025 (%)

The urinary symptoms segment is expected to grow at the fastest CAGR in the market between 2026 and 2035. Hormonal changes after menopause can weaken tissues in the bladder and urethra, leading to symptoms such as frequent urination, mild leakage, or a burning sensation while passing urine. The growing awareness of menopausal health helps women to seek help to treat symptoms.

Distribution Channel Insights

Why Did the Retail Pharmacy Segment Dominate the Market in 2025?

The retail pharmacy segment held a dominant position in the genitourinary syndrome of menopause (GSM) market with a share of 44.60% in 2025. Retail pharmacy is the trusted place for patients to seek treatment of genitourinary syndrome of menopause. Products such as vaginal moisturisers, lubricants, and prescription-based medicines are widely available in local medical stores. Many patients prefer the local pharmacy shop for purchasing medications recommended by doctors without waiting for delivery.

The online pharmacy and e-commerce segment is expected to expand rapidly in the market with a CAGR of 10.60% in the coming years. This option gives the privacy of ordering intimate health products from home. Digital pharmacies and health websites make it easier to access a wide range of products that may not be available in retail pharmacies. The convenience, price comparison, and privacy provided by online pharmacies and e-commerce contribute to the growth of the segment in the genitourinary syndrome of menopause market.

End-user Insights

What made the Hospitals the dominant Segment in the Market?

The hospitals segment dominated the global genitourinary syndrome of menopause (GSM) market with a share of 46.80% in 2025 because hospital remains primary contact place for patients for proper diagnosis and treatment of genitourinary syndrome of menopause. In hospital settings, doctors can examine symptoms carefully and recommend suitable treatment. Patients often rely on hospital care when symptoms become severe. The hospital offers professional guidance and care, making it a dominating segment in the market.

The homecare care and self-care segment is expected to grow with the highest CAGR of 10.30% in the market during the studied years. Many women manage early or mild symptoms of GSM with vaginal moisturizers, lubricants, or wellness products at home. This approach helps to address dryness or irritation without frequent visits to hospitals and clinics.

Regional Insights

North America Genitourinary Syndrome of Menopause (GSM) Market Size and Growth 2026 to 2035

The North America genitourinary syndrome of menopause (GSM) market size is estimated at USD 587.20 million in 2025 and is projected to reach approximately USD 1,187.70 million by 2035, with a 7.30% CAGR from 2026 to 2035.

What Factors Made the North America Region the Dominant Region in the Market?

North America dominated the global genitourinary syndrome of menopause (GSM) market in 2025, with 36.70% share due to high awareness of menopause and related health concerns. Many women are comfortable seeking medical advice when suffering from symptoms such as dryness, irritation, or urinary discomfort. The government is the region, and the regulatory framework is encouraging and approving new and advanced hormone-free drugs to treat genitourinary syndrome of menopause.

U.S. Genitourinary Syndrome of Menopause (GSM) Market Size and Growth 2026 to 2035

The U.S. genitourinary syndrome of menopause (GSM) market size is calculated at USD 440.40 million in 2025 and is expected to reach nearly USD 896.71 million in 2035, accelerating at a strong CAGR of 7.37% between 2026 and 2035.

U.S. Market Trends

The U.S genitourinary syndrome of menopause (GSM) market is witnessing strong growth driven by high healthcare spending and widespread availability of advanced interventional devices and treatments. The hospitals, women's health clinics, and private practices provide guidance and treatment options for genitourinary syndrome of menopause. The growing emphasis on personalized medicine. Early diagnosis and treatment, and rapid adoption of healthcare apps for online consultations, made the country dominate the market.

Which Factors Influence the Fastest Growth of the Asia Pacific Market?

Asia Pacific is expected to grow at the fastest CAGR in the genitourinary syndrome of menopause (GSM) market during the forecast period. Before, women considered these symptoms as normal because discussions about menopause were considered private. The healthcare education and improving access to gynaecological services help women to seek medical consultation. The healthcare infrastructure is improving, and pharmacies and online platforms are also expanding access to supportive medication for treatment. These factors contribute to the growth of the country in the market.

India Market Trends

India is one of the most important markets in the region due to its large population and rising awareness of menopausal health. The gynaecologists and healthcare organizations are spreading awareness about menopausal health, which leads to an increase in the diagnosis rate. The rise of online pharmacies like 1mg and PharmEasy has made treatment more accessible.

Genitourinary Syndrome of Menopause (GSM) Market Value Chain Analysis

Genitourinary Syndrome of Menopause (GSM) Market Companies

• Pfizer
• AbbVie
• Shionogi
• Novo Nordisk
• Mayne Pharma
• Teva Pharmaceutical Industries
• DEKA
• Church and Dwight
• Reckitt
• Haleon
• Bayer
• Viatris
• Organon
• Besins Healthcare
• CooperSurgical

Segments Covered in the Report

By Treatment Type

• Vaginal estrogen therapies
• Oral SERM therapies
• Vaginal DHEA therapies
• Non-hormonal moisturisers and lubricants
• Energy-based devices and procedures

By Delivery Modality

• Prescription therapies
• OTC therapies
• Device-based procedures

By Indication Focus

• Vaginal dryness and irritation
• Dyspareunia
• Urinary symptoms
• Mixed GSM symptom management

By Distribution Channel

• Retail pharmacy
• Hospital pharmacy
• Online pharmacy and e-commerce
• Specialty pharmacy

By End User

• Hospitals
• Gynaecology and women's health clinics
• Ambulatory surgical centres
• Home care and self-care

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa